Naldemedine Approved in China for Opioid-Induced Constipation: A New Option for Cancer Supportive Care
Decision brief
Answer first · skim in under a minute
Naldemedine has been approved in China by the NMPA for the treatment of opioid-induced constipation (OIC), marking a significant advancement in supportive care for cancer patients. This approval by Sino Biopharmaceutical introduces a new therapeutic option to address a common and debilitating side effect of opioid analgesics.
Naldemedine, a peripherally acting μ-opioid receptor antagonist, won National Medical Products Administration approval in China on 27 May 2026 for opioid-induced constipation in adults. Shionogi and Sino Biopharmaceutical’s Hong Kong exchange filing describe mainland commercialization by Chia Tai Tianqing under an exclusive license—expanding a drug already marketed in the U.S., EU and Japan.
Contents9 sections
Key Takeaways
- NMPA approval date: 27 May 2026 for naldemedine tosylate tablets (Symproic / 欣璞落) in adult OIC.
- Chia Tai Tianqing (Sino Biopharm) holds exclusive mainland China marketing rights from Shionogi (deal announced January 2025).
- Naldemedine was already recommended in NICE TA651 and studied in Phase 3 programs such as NCT01993940.
- NRDL listing and provincial tenders—not the approval alone—will set China volume.
What did China approve for naldemedine?
Shionogi announced on 29 May 2026 that Shionogi China received NMPA approval on 27 May 2026 for naldemedine tosylate to treat opioid-induced constipation. Sino Biopharmaceutical’s voluntary announcement on the Hong Kong exchange confirms the Class 1 innovative drug license via Chia Tai Tianqing and the Symproic / 欣璞落 brand.
Primary disclosure: HKEX filing PDF (29 May 2026). An April 2026 Greater Bay Area early launch preceded national approval.
How does naldemedine fit cancer supportive care?
Opioid analgesia remains common in advanced cancer pain. Peripheral μ-opioid receptor antagonists aim to relieve constipation without reversing central analgesia. Naldemedine is already approved in the United States, EU and Japan; China access closes a major geography for Shionogi’s partner network.
UK guidance NICE TA651 covers naldemedine for OIC in adults who have had laxative treatment. Phase 3 evidence includes studies such as NCT01993940 on ClinicalTrials.gov.
What should BD teams watch after NMPA approval?
Approval enables marketing authorization; reimbursement drives uptake. Watch National Reimbursement Drug List negotiations, hospital formulary inclusion and oncology supportive-care guideline uptake. Competitive PAMORA and laxative combinations already exist in China.
U.S. label context for Symproic is available via DailyMed for cross-market safety language, including gastrointestinal perforation warnings typical of the class: DailyMed Symproic label.
For multinational supportive-care portfolios, China’s approval also resets competitive benchmarking against other PAMORAs and against traditional laxative combinations used in oncology wards. Pharmacovigilance commitments and educational programs for opioid prescribers will influence how quickly hospital protocols change after listing.
What remains unproven in the China launch?
NMPA approval does not disclose first-year volume, price or NRDL status. Real-world adherence versus injectable alternatives and hospital tender outcomes will determine commercial impact beyond the May 2026 headline.
How does China access change the global naldemedine map?
With U.S., EU, Japan and now mainland China approvals, naldemedine’s remaining white space is mostly reimbursement depth and guideline uptake, not first regulatory entries. Shionogi’s partner model puts local specialty sales forces in front of oncologists and pain clinics.
China’s oncology supportive-care market is price-sensitive. Without NRDL inclusion, hospital uptake may concentrate in tier-3 centers and private channels. Provincial volume-based procurement could compress margins even after Class 1 innovative recognition.
Safety communication must travel with the launch. Peripheral μ-opioid antagonists carry class warnings about gastrointestinal perforation risk in vulnerable patients. DailyMed U.S. labeling is a useful cross-check for Chinese SmPC translation quality.
For investors in Sino Biopharm, naldemedine is one supportive-care SKU inside a broader oncology portfolio. Model contribution modestly until tender and listing outcomes publish in 2026–2027.
Related NovaPharma coverage
Medical affairs teams should prepare comparative education versus methylnaltrexone and naloxegol where those agents are available, emphasizing oral once-daily convenience and the evidence base behind AGA and ESMO OIC recommendations. Clear messaging on when to stop therapy if severe abdominal symptoms arise is part of responsible launch execution in 2026.
Hospital pharmacy committees will also review drug–drug interaction lists because naldemedine is metabolized in pathways relevant to oncology polypharmacy. Launch kits that include constipation assessment scales and stop rules tend to improve appropriate use versus unstructured prescribing after NMPA approval.
From a portfolio view, Sino Biopharm’s supportive-care expansion complements its oncology pipeline by deepening call-point frequency with the same specialists who prescribe opioids for cancer pain—an adjacency that matters more than the May 2026 approval headline alone.
Frequently Asked Questions
When did China approve naldemedine for OIC?
The NMPA approved naldemedine tosylate tablets for opioid-induced constipation in adults on 27 May 2026, according to Shionogi and Sino Biopharm disclosures dated 29 May 2026.
Who will market naldemedine in mainland China?
Chia Tai Tianqing Pharmaceutical Group, a Sino Biopharmaceutical subsidiary, holds exclusive mainland marketing rights under a January 2025 agreement with Shionogi.
Is naldemedine new to global markets?
No. Naldemedine was already marketed in the United States, European Union, United Kingdom and Japan before the 2026 China NMPA approval.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for Naldemedine.
Unlock full calendar →Investor brief
Download a one-page summary of regulatory impact and competitive context.
Explore drug hub →Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
